Update on the clinical development of cangrelor
Authors:
- José Luis FerreiroJFJosé Luis Ferreiro
- Dominick J AngiolilloDADominick J Angiolillo
- 1 August 2010
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Cardiovascular Therapy
- Vol. 8 (8) , 1069-1077
Abstract
Antiplatelet drugs represent the cornerstone of treatment for cardiovascular atherothrombotic disease. Dual oral antiplatelet therapy with aspirin and oral ADP-receptor antagonists, such as clopidogrel, has been the standard choice for prevention of ischemic events in patients with acute coronary syndrome and in those undergoing percutaneous coronary intervention. However, due to the limitations of clopidogrel, such as interindividual-response variability, drug-drug interactions, slow onset of action and irreversible inhibitory effects, novel antiplatelet agents are under clinical development. Cangrelor is a reversible, potent, competitive inhibitor of the ADP P2Y(12) receptor that is administered intravenously and rapidly achieves near complete inhibition of ADP-induced platelet aggregation. These pharmacological properties make cangrelor a promising drug for clinical use. However, recent large-scale Phase III clinical investigations failed to show significant clinical benefit on the primary end point with cangrelor. This article provides an overview of the current status of knowledge on cangrelor, focusing on its pharmacologic properties and clinical development.Keywords
This publication has 40 references indexed in Scilit:
- Intravenous Platelet Blockade with Cangrelor during PCINew England Journal of Medicine, 2009
- Platelet Inhibition with Cangrelor in Patients Undergoing PCINew England Journal of Medicine, 2009
- Advances in Antiplatelet Therapy: Agents in Clinical DevelopmentThe American Journal of Cardiology, 2009
- Clopidogrel response variability: Current status and future directionsThrombosis and Haemostasis, 2009
- Pharmacology of emerging novel platelet inhibitorsAmerican Heart Journal, 2008
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2007
- Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: Results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trialAmerican Heart Journal, 2007
- ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial InfarctionJACC, 2007
- Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: Results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trialAmerican Heart Journal, 2006
- A novel series of P2T purinoceptor antagonists: definition of the role of ADP in arterial thrombosisTrends in Pharmacological Sciences, 1995